首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases.
【24h】

Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases.

机译:大疱性类天疱疮和其他嗜酸性粒细胞相关的炎症性皮肤病中凝血的激活。

获取原文
获取原文并翻译 | 示例
           

摘要

Bullous pemphigoid (BP) is a skin disease caused by autoantibodies to hemidesmosomal proteins BP180 and BP230, with eosinophils participating in blister formation. Tissue factor (TF), the initiator of coagulation, is embodied within the eosinophil granules and exposed upon activation. We evaluated the coagulation activation in patients with BP (63), chronic urticaria (CU; 20), atopic dermatitis (AD; 14), cutaneous drug reactions (CDRs; six), psoriasis (20), dermatitis herpetiformis (DH; four) and primary cutaneous T cell lymphoma (CTCL; five), and in 40 healthy controls. Prothrombin fragment F1+2 and d-dimer (coagulation markers) were measured by enzyme-linked immunosorbent assay (ELISA) in all plasma samples and BP blister fluid. Skin TF expression was evaluated immunohistochemically in the patients and 20 controls. F1+2 and d-dimer levels were higher in BP plasma than in control plasma (P = 0.0001 for both), and dramatically high in blister fluid; both correlated positively with disease severity, esinophil counts and anti-BP180 antibodies (P = 0.006-0.0001). Plasma F1+2 and d-dimer levels were higher in the CU, AD and CDR patients than in controls (P = 0.0001 for all), but normal in the psoriasis, DH and CTCL patients. Skin TF was expressed in the BP (P = 0.0001), CU (P = 0.0001), AD (P = 0.001) and CDR patients (P = 0.01), but not in the psoriasis, DH or CTCL patients. Co-localization confocal microscopy studies confirmed eosinophils as the source of TF in 10 BP patients. The coagulation cascade is activated in BP and other eosinophil-mediated skin disorders, but not in non-eosinophil driven conditions. This hypercoagulability may contribute to inflammation, tissue damage and, possibly, thrombotic risk.
机译:大疱性类天疱疮(BP)是一种皮肤疾病,由针对半桥粒蛋白BP180和BP230的自身抗体引起,嗜酸性粒细胞参与了水疱的形成。组织因子(TF)是凝血的起始剂,包含在嗜酸性粒细胞内,并在活化后暴露。我们评估了BP(63),慢性荨麻疹(CU; 20),特应性皮炎(AD; 14),皮肤药物反应(CDRs;六个),牛皮癣(20),疱疹样皮炎(DH;四个)患者的凝血活化和原发性皮肤T细胞淋巴瘤(CTCL; 5个),以及40个健康对照。通过酶联免疫吸附测定(ELISA)在所有血浆样品和BP泡罩液中测量凝血酶原片段F1 + 2和d-二聚体(凝血标记)。用免疫组织化学方法评估了患者和20名对照的皮肤TF表达。 BP血浆中的F1 + 2和d-二聚体水平高于对照血浆(两者均为P = 0.0001),而起泡液中则显着较高;两者均与疾病严重程度,嗜酸性粒细胞计数和抗BP180抗体呈正相关(P = 0.006-0.0001)。 CU,AD和CDR患者的血浆F1 + 2和d-二聚体水平高于对照组(所有患者P = 0.0001),但在牛皮癣,DH和CTCL患者中正常。皮肤TF在BP(P = 0.0001),CU(P = 0.0001),AD(P = 0.001)和CDR患者(P = 0.01)中表达,但在牛皮癣,DH或CTCL患者中不表达。共定位共聚焦显微镜研究证实嗜酸性粒细胞是10例BP患者的TF来源。在BP和其他嗜酸性粒细胞介导的皮肤疾病中,凝血级联反应被激活,但在非嗜酸性粒细胞驱动的情况下则未激活。这种过度凝结可能会导致炎症,组织损伤,甚至可能导致血栓形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号